|
37
|
109
|
9ysoA |
Human dctpp1 bound to a class ii inhibitor |
|
36
|
109
|
9yspA |
Human dctpp1 bound to a class iii inhibitor |
|
37
|
110
|
9ysnA |
Human dctpp1 bound to a class i inhibitor |
|
82
|
305
|
9eeiA |
Crystal structure of the sars-cov-2 omicron nsp5 main protease (mpro) e166v mutant in complex with inhibitor gc376 |
|
87
|
306
|
9eetA |
Crystal structure of the sars-cov-2 nsp5 main protease (mpro) e166v mutant in complex with inhibitor gc376 |
|
76
|
301
|
9eevA |
Crystal structure of the sars-cov-2 omicron nsp5 main protease (mpro) e166v mutant in complex with inhibitor nirmatrelvir (pf-07321332) |
|
52
|
245
|
9y0kH |
Structure of plasmodium falciparum 20s proteasome with bound j80 |
|
57
|
245
|
9y0kG |
Structure of plasmodium falciparum 20s proteasome with bound j80 |
|
66
|
250
|
9y0kA |
Structure of plasmodium falciparum 20s proteasome with bound j80 |
|
56
|
212
|
9y0kM |
Structure of plasmodium falciparum 20s proteasome with bound j80 |
|
50
|
195
|
9y0kK |
Structure of plasmodium falciparum 20s proteasome with bound j80 |
|
58
|
210
|
9y0kL |
Structure of plasmodium falciparum 20s proteasome with bound j80 |
|
61
|
243
|
9y0kN |
Structure of plasmodium falciparum 20s proteasome with bound j80 |
|
59
|
234
|
9y0kF |
Structure of plasmodium falciparum 20s proteasome with bound j80 |
|
52
|
227
|
9y0kB |
Structure of plasmodium falciparum 20s proteasome with bound j80 |
|
57
|
238
|
9y0kE |
Structure of plasmodium falciparum 20s proteasome with bound j80 |
|
55
|
233
|
9y0kD |
Structure of plasmodium falciparum 20s proteasome with bound j80 |
|
47
|
221
|
9y0kI |
Structure of plasmodium falciparum 20s proteasome with bound j80 |
|
44
|
215
|
9y0kJ |
Structure of plasmodium falciparum 20s proteasome with bound j80 |
|
60
|
240
|
9y0kC |
Structure of plasmodium falciparum 20s proteasome with bound j80 |
|
95
|
269
|
9d54A |
Crystal structure of kpc-2 complexed with compound 12 |
|
47
|
245
|
9nloA |
Escherichia coli signal peptidase i delta 2-76 p84a in complex with lipopeptide inhibitor |
|
0
|
9
|
9puzE |
Hras complex with um0153030 compound |
|
54
|
167
|
9pulA |
Hras complex with um0143525 compound |
|
55
|
166
|
9puzA |
Hras complex with um0153030 compound |
|
64
|
166
|
9puqA |
Hras complex with um0152248 compound |
|
59
|
166
|
9pu8A |
Hras complex with um0140693 compound |
|
61
|
166
|
9pvfA |
Kras complex with um0152533 compound |
|
0
|
7
|
9pu1C |
Hras complex with um0140401 compound |
|
56
|
167
|
9putA |
Hras complex with um0152535 compound |
|
0
|
9
|
9pulE |
Hras complex with um0143525 compound |
|
0
|
7
|
9pu3C |
Hras complex with um0140692 compound |
|
0
|
9
|
9putB |
Hras complex with um0152535 compound |
|
0
|
8
|
9punE |
Hras complex with um0148697 compound |
|
0
|
7
|
9pu8C |
Hras complex with um0140693 compound |
|
0
|
9
|
9pveI |
Hras complex with um0152533 compound |
|
59
|
167
|
9pu1A |
Hras complex with um0140401 compound |
|
56
|
166
|
9punA |
Hras complex with um0148697 compound |
|
0
|
9
|
9pvfI |
Kras complex with um0152533 compound |
|
0
|
7
|
9puqD |
Hras complex with um0152248 compound |
|
58
|
168
|
9pveA |
Hras complex with um0152533 compound |
|
62
|
165
|
9pu3A |
Hras complex with um0140692 compound |
|
47
|
236
|
10mvA |
N-alkyl & n-aryl aminopyrazole spirocarbamates: a two-pronged lead optimization strategy to identify orally bioavailable plasma kallikrein inhibitors complex with compound 15 ((3'r)-1'-(5-amino-1-phenyl-1h-pyrazole-4-carbonyl)-6-chloro-5-fluorospiro[[3,1]benzoxazine-4,3'-piperidin]-2(1h)-one) |
|
50
|
239
|
10kzA |
N-alkyl & n-aryl aminopyrazole spirocarbamates: a two-pronged lead optimization strategy to identify orally bioavailable plasma kallikrein inhibitors |
|
52
|
239
|
10qsA |
N-alkyl & n-aryl aminopyrazole spirocarbamates: a two-pronged lead optimization strategy to identify orally bioavailable plasma kallikrein inhibitors compound 13 ((3'r)-1'-{5-amino-1-[(2s)-1,1,1-trifluorobutan-2-yl]-1h-pyrazole-4-carbonyl}-6-chloro-5-fluorospiro[[3,1]benzoxazine-4,3'-piperidin]- |
|
45
|
236
|
10mwA |
N-alkyl & n-aryl aminopyrazole spirocarbamates: a two-pronged lead optimization strategy to identify orally bioavailable plasma kallikrein inhibitors compound 25 ((3'r)-1'-{(1p)-5-amino-1-[2-(trifluoromethoxy)phenyl]-1h-pyrazole-4-carbonyl}-6-chloro-5-fluorospiro[[3,1]benzoxazine-4,3'-piperidin] |
|
48
|
239
|
10lrA |
N-alkyl & n-aryl aminopyrazole spirocarbamates: a two-pronged lead optimization strategy to identify orally bioavailable plasmakallikrein inhibitors complex with compound 4 ((3'r)-1'-(5-amino-1-benzyl-1h-pyrazole-4-carbonyl)-6-chloro-5-fluorospiro[[3,1]benzoxazine-4,3'-piperidin]-2(1h)-one) |
|
209
|
708
|
9xzzA |
Human prolyl endopeptidase (prep) - complex with kyp2047 |
|
80
|
246
|
9zovA |
Oxa-23-jdb/pq-1-219, 60 min complex |
|
82
|
246
|
9zouA |
Oxa-23-jdb/pq-1-219, 40 min complex |
